Why the study?
Does first-line cytotoxic chemotherapy (ifosfamide-containing regimens) improve treatment activity compared to anthracycline alone in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma?
Does first-line cytotoxic chemotherapy (ifosfamide-containing regimens) improve treatment activity compared to anthracycline alone in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma?
The combination of doxorubicin and ifosfamide appears to be the most active first-line chemotherapy regimen available for fit patients with advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma.
Does not support changing first-line anthracycline use; leaves open whether ifosfamide addition improves activity in advanced liposarcoma.
Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA-LPS. Ifosfamide-containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma.
No takes yet. Share an insight, caveat, or question.
Stacchiotti et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: